Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus

Arthritis & Rheumatism

Volumn 33, Issue 5, 1990, Pages 634-643

  Ter Borg, E J ^a   Horst, G ^a   Hummel, E J ^a   Limburg, P C ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA ANTIBODY;

ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; COMPLEMENT 3; COMPLEMENT 4; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORECASTING; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0025374697     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780330505     Document Type: Article

References (35)

1. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.
2. The relationship of anti‐DNA antibody idiotypes and anti‐cardiolipin antibodies to disease activity in systemic lupus erythematosus.
3. Measurement of serum DNA‐binding activity in systemic lupus erythematosus.
4. Correlation between levels of DNA antibodies and clinical disease activity in SLE: retrospective evaluation.
5. Anti‐native DNA detection by the Crithidia luciliae method: an improved guide to the diagnosis and clinical management of systemic lupus erythematosus.
6. Anti‐DNA activity in systemic lupus erythematosus: a diagnostic and therapeutic guide.
7. Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease.
8. Immunologic factors and clinical activity in lupus erythematosus.
9. Longitudinal studies of anti‐DNA antibody levels in SLE.
10. Immune complexes, complement, and anti‐DNA in exacerbations of systemic lupus erythematosus (SLE).
11. Complement fixation by anti‐ds DNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity.
12. Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus.
13. Serologically active clinically quiescent systemic lupus erythematosus.
14. Immunopathogenesis of systemic lupus erythematosus.
15. Avidity of antibodies to dsDNA: comparison of IFT on Crithidia luciliae, Farr assay, and PEG assay.
16. Immunologic events preceding clinical exacerbation of systemic lupus erythematosus.
17. Anti‐dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus.
18. Predictive value of complement profiles and anti‐ds DNA in systemic lupus erythematosus.
19. Prognostic significance of DNA‐binding capacity patterns in patients with lupus nephritis.
20. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus.
21. The 1982 revised criteria for the classification of systemic lupus erythematosus.
22. Measurement of systemic lupus erythematosus activity in clinical research.
23. B‐cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis.
24. Immunology of DNA. III. Crithidia luciliae: a simple substrate for the determination of anti‐ds DNA with the immunofluorescence technique.
25. The first international standard for antibodies to double stranded DNA.
26. Free DNA in serum and plasma from normal adults.
27. Specificity of anti‐Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens.
28. Measurement of anti‐DNA antibodies; a reappraisal using five different methods.
29. A longitudinal study of high and low avidity antibodies to double‐stranded DNA in systemic lupus erythematosus.
30. Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus.
31. Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.
32. Cross‐reactivity of human and murine anti‐DNA antibodies with heparan sulfate.
33. Useful laboratory measurements in the management of systemic lupus erythematosus.
34. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations.